397 related articles for article (PubMed ID: 10666494)
1. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy.
Fujita T; Satomura A; Hidaka M; Ohsawa I; Endo M; Ohi H
Calcif Tissue Int; 2000 Mar; 66(3):195-9. PubMed ID: 10666494
[TBL] [Abstract][Full Text] [Related]
2. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
Struys A; Snelder AA; Mulder H
Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
[TBL] [Abstract][Full Text] [Related]
3. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
Diamond T; Campbell J; Bryant C; Lynch W
Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
[TBL] [Abstract][Full Text] [Related]
4. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment.
Pitt P; Li F; Todd P; Webber D; Pack S; Moniz C
Thorax; 1998 May; 53(5):351-6. PubMed ID: 9708225
[TBL] [Abstract][Full Text] [Related]
5. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
Fogelman I; Herd RJ; Blake GM; Balena R
Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
[TBL] [Abstract][Full Text] [Related]
6. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
7. Effects of steroid treatment on bone mineral metabolism in children with glucocorticoid-sensitive nephrotic syndrome.
Koşan C; Ayar G; Orbak Z
West Indian Med J; 2012 Sep; 61(6):627-30. PubMed ID: 23441359
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
9. Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist.
Zamberlan N; Castello R; Gatti D; Rossini M; Braga V; Fracassi E; Adami S
Osteoporos Int; 1997; 7(2):133-7. PubMed ID: 9166393
[TBL] [Abstract][Full Text] [Related]
10. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease.
von Tirpitz C; Epp S; Klaus J; Mason R; Hawa G; Brinskelle-Schmal N; Hofbauer LC; Adler G; Kratzer W; Reinshagen M
Eur J Gastroenterol Hepatol; 2003 Nov; 15(11):1165-70. PubMed ID: 14560148
[TBL] [Abstract][Full Text] [Related]
11. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
Watts NB; Becker P
Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.
Cortet B; Hachulla E; Barton I; Bonvoisin B; Roux C
Rev Rhum Engl Ed; 1999 Apr; 66(4):214-9. PubMed ID: 10339777
[TBL] [Abstract][Full Text] [Related]
13. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
Diamond T; McGuigan L; Barbagallo S; Bryant C
Am J Med; 1995 May; 98(5):459-63. PubMed ID: 7733124
[TBL] [Abstract][Full Text] [Related]
14. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
15. Circadian rhythms in serum bone markers and their relation to the effect of etidronate in rats.
Shao P; Ohtsuka-Isoya M; Shinoda H
Chronobiol Int; 2003 Mar; 20(2):325-36. PubMed ID: 12723888
[TBL] [Abstract][Full Text] [Related]
16. Parathyroidectomy for primary hyperparathyroidism induces positive uncoupling and increases bone mineral density in cancellous bones.
Abe Y; Ejima E; Fujiyama K; Kiriyama T; Ide A; Sera N; Tominaga T; Ashizawa K; Yokoyama N; Eguchi K
Clin Endocrinol (Oxf); 2000 Feb; 52(2):203-9. PubMed ID: 10671948
[TBL] [Abstract][Full Text] [Related]
17. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
Shiraki M; Fukunaga M; Kushida K; Kishimoto H; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H
Osteoporos Int; 2003 May; 14(3):225-34. PubMed ID: 12730746
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
Kitatani K; Nakatsuka K; Naka H; Miki T; Morii H; Nishizawa Y
J Bone Miner Metab; 2003; 21(4):217-24. PubMed ID: 12811626
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density and metabolism in children with congenital hypothyroidism after prolonged L-thyroxine therapy.
Leger J; Ruiz JC; Guibourdenche J; Kindermans C; Garabedian M; Czernichow P
Acta Paediatr; 1997 Jul; 86(7):704-10. PubMed ID: 9240877
[TBL] [Abstract][Full Text] [Related]
20. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
